Arcturus Therapeutics Holdings (ARCT)
(Delayed Data from NSDQ)
$12.30 USD
+0.09 (0.74%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $12.30 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth A Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
Arcturus Therapeutics Holdings Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
ARCT 12.30 +0.09(0.74%)
Will ARCT be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ARCT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ARCT
Wall Street Analysts Think Arcturus Therapeutics (ARCT) Could Surge 371.35%: Read This Before Placing a Bet
Wall Street Analysts Believe Arcturus Therapeutics (ARCT) Could Rally 503.6%: Here's is How to Trade
ARCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Arcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimates
Earnings Preview: Arcturus Therapeutics (ARCT) Q1 Earnings Expected to Decline
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
Other News for ARCT
ARCT Crosses Above Key Moving Average Level
Arcturus Therapeutics (ARCT) Maintains Sector Outperform; Price Target Raised | ARCT Stock News
Arcturus Therapeutics price target raised by $3 at Scotiabank, here's why
Arcturus Therapeutics: High Hopes, High Hurdles For Its mRNA Pipeline
Expert Outlook: Arcturus Therapeutics Through The Eyes Of 5 Analysts